ResMed At $250: Missed Opportunity Or A Trap In The Making?
ResMed (RMD) stock is currently at a fascinating juncture. It is trading at a low price, and if you decide to invest in it, you are wagering on a company that is demonstrating reasonable growth, maintaining solid cash flow and margin, has a low-debt capital structure, and is fairly valued.
RMD Stock Up Following Q2 Earnings & Revenue Beat, Margins Expand
Resmed shares rise after Q2 EPS and revenues beat expectations, with the gross and operating margins expanding sharply across core segments.
ResMed: Facing A Potentially Dream-Disrupting Dose - Strong Sell
ResMed: Facing A Potentially Dream-Disrupting Dose - Strong Sell
ResMed Inc. (RMD) Q2 2026 Earnings Call Transcript
ResMed Inc. (RMD) Q2 2026 Earnings Call Transcript
ResMed (RMD) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for ResMed (RMD) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ResMed (RMD) Q2 Earnings and Revenues Beat Estimates
ResMed (RMD) came out with quarterly earnings of $2.81 per share, beating the Zacks Consensus Estimate of $2.69 per share. This compares to earnings of $2.43 per share a year ago.
Here's Why ResMed (RMD) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are Medical Stocks Lagging ResMed (RMD) This Year?
Here is how ResMed (RMD) and Compass Therapeutics, Inc. (CMPX) have performed compared to their sector so far this year.
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Stay Ahead of the Game With ResMed (RMD) Q2 Earnings: Wall Street's Insights on Key Metrics
Besides Wall Street's top-and-bottom-line estimates for ResMed (RMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Resmed's Q2 Earnings on Deck: What's in Store for the Stock?
RMD is set to report Q2 results on Jan. 29, with revenues likely to jump 8.3% and EPS 10.3% as masks, devices and software drive growth.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
